- PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- PepGen to Participate in Upcoming Investor Conferences
- PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
- PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
- PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
- PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
- Mary Beth DeLena Joins PepGen as General Counsel and Secretary
- PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
- PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
More ▼
Key statistics
On Tuesday, PepGen Inc (PEPG:NSQ) closed at 16.32, -12.82% below its 52-week high of 18.72, set on Jun 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.04 |
---|---|
High | 18.04 |
Low | 16.31 |
Bid | 16.00 |
Offer | 26.11 |
Previous close | 16.32 |
Average volume | 245.96k |
---|---|
Shares outstanding | 32.42m |
Free float | 32.41m |
P/E (TTM) | -- |
Market cap | 529.05m USD |
EPS (TTM) | -3.25 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼